Hi, good morning. My name is Iván Martínez, I'm founder and CEO of Robopedics. Well, I think that we should be here around 25 people. So I have very bad news because five of you will suffer a stroke during your lifetime. And what's worse, one of you will stay in a wheelchair for the rest of your life of the ones you are here. Yes, that's because we are talking about stroke and stroke is the third leading cause of disability worldwide. And what's more, only in Europe, it represents cycles of more than 60 billion euros. Well, I'm here to talk about stroke, but also want to share a personal story and the story of my father, he suffered a stroke eight years ago. And unfortunately, after a few months of rehabilitation doctor told us that he was going to stay here in a wheelchair forever. And of course, at the beginning, you don't believe it? And we didn't. And we searched for alternative solutions. And then what we found is something called exoskeletons. Exoskeletons are what you see here are all the devices that have an engine that power your legs, if you don't have a strength enough, okay. And with that, it's true that Wi Fi could work. It was just a clinical trial, like he could set up and work. And that was amazing for us. And so of course, why we decided, okay, we want, we want to buy one of those devices want to bring it at home, we want to use it to help my father. But unfortunately, we couldn't. And you know why? Because exoskeletons, they are so expensive, they are so heavy, they are intended for rehabilitation. So de facto, you only find those devices in a hospital. And you can use them in the medical supervision. Or if you want to use at home as we wanted, we couldn't add that was really painful and also frustrating. Why? Because we knew there was a technology solution for my father, restricted to a few hospitals, but people like him, and millions are at home with no solution. And that's very hard. And then, well, I made my decision. I'm a mechanical engineer. So I decided, Okay, I'm going to get one myself. And I did it. So I worked on it for five years, until by 2020, I had already developed a proof of concept, it was more or less functional. But I'm sure that all of us will remember to the 2020 COVID. For God, my father was one of those who passed by passed away with COVID. And that was very hard to me. I lost my father. But on top of that, I was sure that I had failed him. Because I didn't arrive in time, I had something that he that could help him. But I didn't arrive in time. So it was very hard to me, it took me months until I realized that there were millions like him in a wheelchair worldwide, that for that technology could also help them. And that's why we created Robopedics. So to be clear, our purpose is to democratize and existing technology that can help people like my father stroke, me pledging to stand up and walk. But we want to do it at home every day, and without any medical supervision. And we want to improve the quality of life and the health of that people, not to rehabilitate, at least not today, because people like my father would have never rehabilitated. And that's a fact. And well, now the good news, we're just here this week. So start Robotic Artosis our product, a new category, and it will make it possible 80% cheaper and 60% Lighter than existing solutions. And you might think this is a fantasy, but it is another look. This is the main feature of our device, just one like, why? Because we are conceived for stroke. And in stroke, you have one half of your body paralyzed. So only one leg? Well, there's solutions in the market. They are designed for rehabilitation with spinal cord injury where you need two legs. And that tiny detail makes a big difference. Because from the very beginning our design, we can cut cost and wait to a half only by that. But of course that's not all, we have developed a very low investment manufacturing process. And we have an engineering power which is an expert in aeronautics, and many more things. And that's how we are going to do it. Okay, we're just here to live. This is our first test with an accurate stroke disabled in a hospital. And there we proved that our device was working. And what you see here is the current state of development. This is the fourth version and we are still ongoing in the design. We'll give you more details later. Okay, talking business model is also disruptive because for us, our customer is the disabled, which is in a wheelchair, and we want to sell him directly awake for just 500 euros per month. And we will include training, technical support, customer service, and many other things. And that's something we call device as a service. And as you might see, the price is absolutely nothing if you compare it with 100,000 euros that next solution can cost. So if we could talk about promotion And we will do it both online and offline. And we will focus on the community of stakeholders around the stroke and IKEA, what we will get out there patient, the families, the doctors, the hospital insurance companies, and many more, we will provide, deliver the device awake and also provide the services through existing rehabilitation centers, which are close to the to the user, and that will be our partners. And finally, our manufacturing process will just be assembly of commercial parts and 3d printing. And as I mentioned, we don't require a large investment for doing so what the market, our obsession is to arrive as quick as possible to market and that's why we are going to start in Spain and stroke in Spanish. And that's my natural market, the company is a Spanish, but it's also the best test in place for our device in the worst because we are the country with a longest longevity of the population. And here we have 90 90,000 people like my father and our wheelchair disabled. But of course, stroke is not a local problem. Unfortunately, it's a worldwide phenomenon. This is so we will increase we will grow in different international markets, we will evolve our device to help in all diseases not only in this stroke, but we can also evolve the technology for our applications, we will start home but we will also the rehabilitation and we can rehabilitate in the hospital, but also home. And when not, we can evolve the technology to enhance the activities of daily living of 700 million elderly population worldwide. So we that combination of markets and application we will make that that market will grow exponentially. So a little bit of history, we created the company in 2021. By 2022, we raised half a million was around led by ESA is on top, this is a school in Spain, worldwide, and also with capital. So it's a specialized biotech crowd fund. So without money, we are developing our device, and it should be right in the coming six months or less. And then right now we have we are working our second round of 1.7 million equity we have already committed 1.2. On that should help us to achieve the regulatory clearance of the device and to rise to market by the end of 2024 beginning of 2025 for the scope. Okay. So at that moment, we will start delivering our device. As he mentioned, our probably the most of the seeds will be those renting of 500 euros, we can also offer that right less than 20,000. And our perspective are that I'm showing here only the Spanish market we expect to be in breakeven by 2026. To keep on growing up to the coming years, until we arrived around 100 euros, net, net sales, okay, but 100 million euros and we are talking about 17% of Aveda and generating 12 million cash every year. That's only Spain. Right now we were working on the forecast for Europe and the first figures we have a show around 500 million euro euros in Europe by 2030. Okay to make it real, of course, we need the best talent and the best partners. And again, good news, we have it. Look, this is a very senior team. They are not students 106 years of experience and we all with you with us. There you will see some of the top performing institutions in Barcelona in health and technology. So we go we're perfectly if we have a 60 degree needs of the company. And to finish why invest in Robopedics? Well, of course, that's for investors, we think this an excellent investment opportunity we took in our 500 million so in Europe 17% of EBITDA. But it's true that in the latest year they are key partners that are investing are making acquisitions in this in this market. Second, disruptive we are talking about disruptive product, okay, it's a new category and disruptive business model device as a service direct to consumer, exponential and scalable international markets, different applications. Also, we are aligned with some major global trends. ageing of the population, one of the major diseases a stroke a lot public health infrastructures due to homebase healthcare. But what that's more important as this to me is that our project has impact we are talking here about improving the quality of life like people have of people like my father in a wheelchair. I finished with this remember that car Nissan LEAF, for first mass produced electrical car, they didn't succeed who succeed. Tesla, Mr. Elon Musk, he created a new category A key democratized electrical car. It wasn't of Nissan LEAF robotics. We haven't created the robotic solution for disabled but we are going to change the game. We are going into new technology and we will democratize the exit of this technology. Thank you very much.